A sweeping examination of the core issues of sexual politics, bell hook's new book Feminist Theory: from margin to center argues that the contemporary feminist movement must establish a new direction for the 1980s. Continuing the debates surrounding her controversial first book, Ain't I A Woman, bell hooks suggests that feminists have not succeeded in creating a mass movem A sweeping examination of the core issues of sexual politics, bell hook's new book Feminist Theory: from margin to center argues that the contemporary feminist movement must establish a new direction for the 1980s. Continuing the debates surrounding her controversial first book, Ain't I A Woman, bell hooks suggests that feminists have not succeeded in creating a mass movement against sexist oppression because the very foundation of women's liberation has, until now, not accounted for the complexity and diversity of female experience.

/pdf/feminist-theory-from-margin-to-center-2g1w0whgub.pdf

Feminist Theory: From Margin to Center

Hepatocellular carcinoma

No adjuvant treatment has been established for patients who remain at high risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We aimed to assess the efficacy of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with high-risk hepatocellular carcinoma.In the global, open-label, phase 3 IMbrave050 study, adult patients with high-risk surgically resected or ablated hepatocellular carcinoma were recruited from 134 hospitals and medical centres in 26 countries in four WHO regions (European region, region of the Americas, South-East Asia region, and Western Pacific region). Patients were randomly assigned in a 1:1 ratio via an interactive voice-web response system using permuted blocks, using a block size of 4, to receive intravenous 1200 mg atezolizumab plus 15 mg/kg bevacizumab every 3 weeks for 17 cycles (12 months) or to active surveillance. The primary endpoint was recurrence-free survival by independent review facility assessment in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT04102098.The intention-to-treat population included 668 patients randomly assigned between Dec 31, 2019, and Nov 25, 2021, to either atezolizumab plus bevacizumab (n=334) or to active surveillance (n=334). At the prespecified interim analysis (Oct 21, 2022), median duration of follow-up was 17·4 months (IQR 13·9-22·1). Adjuvant atezolizumab plus bevacizumab was associated with significantly improved recurrence-free survival (median, not evaluable [NE]; [95% CI 22·1-NE]) compared with active surveillance (median, NE [21·4-NE]; hazard ratio, 0·72 [adjusted 95% CI 0·53-0·98]; p=0·012). Grade 3 or 4 adverse events occurred in 136 (41%) of 332 patients who received atezolizumab plus bevacizumab and 44 (13%) of 330 patients in the active surveillance group. Grade 5 adverse events occurred in six patients (2%, two of which were treatment related) in the atezolizumab plus bevacizumab group, and one patient (<1%) in the active surveillance group. Both atezolizumab and bevacizumab were discontinued because of adverse events in 29 patients (9%) who received atezolizumab plus bevacizumab.Among patients at high risk of hepatocellular carcinoma recurrence following curative-intent resection or ablation, recurrence-free survival was improved in those who received atezolizumab plus bevacizumab versus active surveillance. To our knowledge, IMbrave050 is the first phase 3 study of adjuvant treatment for hepatocellular carcinoma to report positive results. However, longer follow-up for both recurrence-free and overall survival is needed to assess the benefit-risk profile more fully.F Hoffmann-La Roche/Genentech. 

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

This is surely the most ambitious and the most accomplished study of affluent post-World War II democratic welfare states. It uses statistical, case study, and comparative historical methods to describe and explain the course of social welfare policy over the second half of the twentieth century in 16 nations. Quantitatively, the study examines social insurance and service programs, major public expenditure and revenue aggregates, and an array of fine-grained indicators of state redistributive and safety net outcomes, from 1960 through 1994. Somewhat more qualitatively, the study extends its reach to encompass job and gender, labor market, and educational policies over the whole 1945–1996 period. Using both quantitative and qualitative methods of explanatory analysis, the work assesses various accounts of welfare state development and crisis, in particular, its authors' institutionally amplified, class-analytical political resource theory.

https://www.cambridge.org/core/services/aop-cambridge-core/content/view/ECC0C969124100F14A985F6FDE7BD4D5/S0003055402000242a.pdf/div-class-title-development-and-crisis-of-the-welfare-state-parties-and-policies-in-global-markets-by-evelyne-huber-and-john-d-stephens-chicago-university-of-chicago-press-2001-368p-54-00-cloth-18-00-paper-div.pdf

Development and Crisis of the Welfare State: Parties and Policies in Global Markets. By Evelyne Huber and John D. Stephens. Chicago: University of Chicago Press, 2001. 368p. $54.00 cloth, $18.00 paper.

Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.

/pdf/women-work-and-welfare-a-case-study-of-germany-the-uk-and-5df6cjpos8.pdf

Women, Work And Welfare: A Case Study Of Germany, The Uk, And Sweden

Handle everyday research tasks with reliable, citation-backed results

Your personal Research Agent to handle research tasks with citation-backed results

Popular Tasks used by Researchers

How can I help with your research?

Meet SciSpace

Get more enhanced response by uploading the PDFs you want me to reference.

No relevant PDFs in your library

SciSpace is the AI research assistant for academics. Run systematic literature reviews on 280M+ papers, and write papers with cited sources. Trusted by 1M+ students, PhDs & researchers.

SciSpace | AI for Research

Analyze PDFs

Code & Manuscripts

Funding & Grants

Literature & Patents

Medical & Clinical Data

Systematic Review

Visualize & Present

Web & Data

Build a Google Scholar-like website for your research.

Build a website

Create charts and images for your research

Create a Chart

Write a paper for submission to a journal

Draft a manuscript

Patent Search

Design eye-catching scientific posters in minutes.

Scientific Poster Generation

Systematic Literature Review

One task is running at the moment. Your messages will be shown right after.

Drag and drop or click here to browse

Loved by <highlight>1 million+</highlight> researchers

Extract a list of specific topics and their sources from unstructured text

Topics

Compare and analyze relevant papers that matches with your search

Papers

Get insights from PDFs and bookmarked papers from your library

My library

Recent searches

Try searching for:

Catch AI-generated content in scholarly and non-scholarly content

{ai} Detector

Ai Writer

Get PDF Summaries, highlighted text explanations 

Chat with PDF

Effortlessly create in-text citations and bibliographies in APA and 2,500 other formats

Citation generator

Get explanations, summaries, and answers on academic papers

Ease up your research workflow with {scispace}'s cohort of exciting AI tools

Elevate your academic writing skills and convey your ideas the way you want

Paraphraser

Explore our range of reading and writing tools

Your file is being prepared and should be ready in a few minutes. If it's a large file, it might take a bit longer. You can close this window, and we'll email you the file when it's done.

You have reached a maximum limit of <strong>{limit}</strong> columns in the table. Remove at least <strong>1</strong> column to add or create another one.

Meredith Legg

Author Tools

Chat about Author

Papers

Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.

Women, Work And Welfare: A Case Study Of Germany, The Uk, And Sweden